The fact that hepatic FSP27 is induced under pathologic conditions and correlates with lipid accumulation (3, 5, 10, 14, 15) suggests that FSP27 might be a therapeutic target for NAFLD/NASH patients. Here, CIDEC is linked to metabolic dysfunction-associated steatotic liver disease.